EP3589646A4 - Compositions à base de cd19 et méthodes pour l'immunothérapie - Google Patents

Compositions à base de cd19 et méthodes pour l'immunothérapie Download PDF

Info

Publication number
EP3589646A4
EP3589646A4 EP18760420.2A EP18760420A EP3589646A4 EP 3589646 A4 EP3589646 A4 EP 3589646A4 EP 18760420 A EP18760420 A EP 18760420A EP 3589646 A4 EP3589646 A4 EP 3589646A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18760420.2A
Other languages
German (de)
English (en)
Other versions
EP3589646A1 (fr
Inventor
Vipin Suri
Michael Joseph BRISKIN
Brian DOLINSKI
Kutlu Goksu ELPEK
Dan Jun LI
Scott Francis HELLER
Michelle Lynn OLS
Dexue Sun
Nicole KOSMIDER
Abhishek KULKARNI
Vijaya BALAKRISHNAN
Tucker EZELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obsidian Therapeutics Inc
Original Assignee
Obsidian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obsidian Therapeutics Inc filed Critical Obsidian Therapeutics Inc
Publication of EP3589646A1 publication Critical patent/EP3589646A1/fr
Publication of EP3589646A4 publication Critical patent/EP3589646A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
EP18760420.2A 2017-03-03 2018-03-02 Compositions à base de cd19 et méthodes pour l'immunothérapie Pending EP3589646A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762466601P 2017-03-03 2017-03-03
US201762484052P 2017-04-11 2017-04-11
PCT/US2018/020741 WO2018161017A1 (fr) 2017-03-03 2018-03-02 Compositions à base de cd19 et méthodes pour l'immunothérapie

Publications (2)

Publication Number Publication Date
EP3589646A1 EP3589646A1 (fr) 2020-01-08
EP3589646A4 true EP3589646A4 (fr) 2021-01-20

Family

ID=63371272

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18760420.2A Pending EP3589646A4 (fr) 2017-03-03 2018-03-02 Compositions à base de cd19 et méthodes pour l'immunothérapie

Country Status (8)

Country Link
EP (1) EP3589646A4 (fr)
JP (3) JP7341900B2 (fr)
KR (1) KR102746901B1 (fr)
CN (1) CN110831961B (fr)
AU (2) AU2018227583B2 (fr)
CA (1) CA3055202A1 (fr)
SG (2) SG11201907922PA (fr)
WO (1) WO2018161017A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11201912010XA (en) 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
MA51154A (fr) 2017-12-15 2020-10-21 Aleta Biotherapeutics Inc Variants de cd19
CN119752801A (zh) * 2018-08-01 2025-04-04 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
EP3856910B1 (fr) * 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Vecteurs d'expression pour systèmes d'expression eucaryotes
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
IL277414B2 (en) * 2018-11-06 2025-04-01 Immunitybio Inc NK–92 cells with chimeric antigen receptor modification
EP4063510A1 (fr) * 2018-11-07 2022-09-28 Akouos, Inc. Utilisation de vecteurs viraux adéno-associés pour corriger des défauts de gène/exprimer des protéines dans des cellules ciliées et de soutien dans l'oreille interne
CA3120563A1 (fr) 2018-11-26 2020-06-04 Nkarta, Inc. Procedes d'expansion simultanee de multiples types de cellules immunitaires, compositions associees et utilisations de celles-ci dans l'immunotherapie contre le cancer
WO2020123716A1 (fr) * 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Il12 liée à la membrane, compositions et procédés de régulation accordable
CN116479022A (zh) * 2018-12-12 2023-07-25 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
KR20210121136A (ko) * 2019-01-29 2021-10-07 상하이 지아오통 유니버시티 키메라 항원 수용체 및 그 용용
US12241061B2 (en) 2019-02-04 2025-03-04 National University Corporation Ehime University CAR library and scFv manufacturing method
KR20210132668A (ko) * 2019-02-21 2021-11-04 아르벨 리미티드 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
WO2020172631A2 (fr) 2019-02-21 2020-08-27 Xencor, Inc. Protéines de fusion fc d'il-10 non ciblées et ciblées
US12590135B2 (en) 2019-03-01 2026-03-31 Universität Für Bodenkultur Wien Stabilized extracellular domain of CD19
WO2020180882A1 (fr) 2019-03-05 2020-09-10 Nkarta, Inc. Récepteurs d'antigènes chimériques anti-cd19 et leurs utilisations en immunothérapie
CN114174327A (zh) * 2019-03-08 2022-03-11 黑曜石疗法公司 用于可调整调控的cd40l组合物和方法
KR20210149251A (ko) * 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020190771A1 (fr) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adaptateur chimérique, protéines de signalisation de kinase et leur utilisation en immunothérapie
EP3959235B1 (fr) * 2019-04-26 2023-07-26 Allogene Therapeutics, Inc. Récepteurs d'antigènes chimériques résistant au rituximab et leurs utilisations
CN110079504A (zh) * 2019-05-06 2019-08-02 山东大学第二医院 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法
CN110075275B (zh) * 2019-05-15 2023-03-24 苏州大学 IL-36β的应用
JP2022534498A (ja) * 2019-05-29 2022-08-01 オービス ヘルス ソリューションズ エルエルシー キメラ受容体を発現させるための送達ベクターおよび粒子ならびにその使用方法
JP2022537670A (ja) * 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
CA3141927A1 (fr) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Anticorps diriges contre pdl1 et procedes d'utilisation associes
CN110818803B (zh) * 2019-07-24 2023-01-03 浙江启新生物技术有限公司 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用
AU2020331963A1 (en) * 2019-08-19 2022-03-03 Elpis Biopharmaceuticals Anti-CD19 antibodies and uses thereof
US20210128617A1 (en) * 2019-08-27 2021-05-06 The Trustees Of The University Of Pennsylvania SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (fr) * 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
AU2020361683A1 (en) * 2019-10-11 2022-05-19 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
US20230000916A1 (en) * 2019-11-27 2023-01-05 The Trustees Of The University Of Pennsylvania Anti-cd3 scfv and cytokine producing artificial antigen presenting cells
KR20220122642A (ko) * 2019-11-27 2022-09-02 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 T 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집
MX2022008415A (es) * 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
JP7439280B2 (ja) * 2020-02-13 2024-02-27 イミュノファーム テクノロジー カンパニー リミテッド キメラ抗原受容体の最適化
KR20210103975A (ko) * 2020-02-14 2021-08-24 (주)이뮤노텍바이오팜코리아 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
CA3173527A1 (fr) * 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Procedes de generation de cellules nk de type memoire modifiees et compositions de celles-ci
US11896619B2 (en) * 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
EP4204560A4 (fr) * 2020-09-02 2024-10-16 Nkarta, Inc. Expansion et cytotoxicité améliorées de cellules tueuses naturelles modifiées et utilisations associées
JP2023540339A (ja) * 2020-09-04 2023-09-22 インパクト バイオ ユーエスエー インコーポレイテッド 癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物
JP7808298B2 (ja) * 2020-09-04 2026-01-29 Ｈｅａｒｔｓｅｅｄ株式会社 ｉＰＳ細胞の品質改善剤、ｉＰＳ細胞の製造方法、ｉＰＳ細胞、及びｉＰＳ細胞製造用組成物
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
CN112830974B (zh) * 2021-01-08 2022-07-26 深圳市珈钰生物科技有限公司 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113403274B (zh) * 2021-06-28 2023-11-10 上海睿臻迈生物医疗科技有限公司 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
CN114129718B (zh) * 2021-10-19 2024-05-03 华东师范大学 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用
CN114558126B (zh) * 2021-11-04 2024-11-08 苏州大学附属第一医院 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用
CN116789822A (zh) * 2022-03-18 2023-09-22 广东东阳光药业股份有限公司 Claudin18.2人源化抗体及其应用
JP2025522815A (ja) 2022-07-05 2025-07-17 ネオミクス ファーマシューティカルズ リミティド ライアビリティ カンパニー キメラ細胞内シグナル伝達ドメインに連結されたｂｃｍａナノボディを含むキメラ抗原受容体
JP2026509481A (ja) * 2023-03-15 2026-03-19 京都府公立大学法人 ペプチド発現コンストラクトおよびその使用
CN116516007B (zh) * 2023-04-18 2024-01-19 华中科技大学同济医学院附属协和医院 Cd19表达的检测方法
CN116536375B (zh) * 2023-06-28 2023-11-10 北京大学深圳研究生院 merocyclophanes类化合物的化学-酶法合成方法及其应用
WO2025160432A1 (fr) * 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Méthodes et compositions pour améliorer la persistance in vivo et l'efficacité d'une thérapie cellulaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
WO2018231759A1 (fr) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Compositions de pde5 et méthodes d'immunothérapie

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568A (en) 1838-01-09 Sphebometeb for
US451A (en) 1837-11-04 Island
US6531A (en) 1849-06-19 Beed musical instrument
US7094A (en) 1850-02-12 Connecting trucks with car-bodies
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2032914A1 (fr) 1989-12-26 1991-06-27 Peter C.K. Lau Utilisation d'un acide amine n-terminal d'une lipoproteine bacterienne dans des plasmides hybrides pour l'expression in vivo de polypeptides modifies par des lipides
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993018181A1 (fr) 1992-03-13 1993-09-16 Cornell Research Foundation, Inc. Sequence genique synthetique pour un peptide-signal
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
CA2243235C (fr) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
CA2265460A1 (fr) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Vecteur de vaa4 et ses utilisations
CA2267977A1 (fr) 1996-10-16 1998-04-23 Matthew G. Ewend Immunotherapie amelioree par cytokine pour tumeurs cerebrales
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
WO1999014346A2 (fr) 1997-09-19 1999-03-25 Sequitur, Inc. THERAPIES GENIQUES A BASE D'ARNm SENS
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
CA2415902A1 (fr) 2000-07-10 2002-01-17 Xencor Automatisation de conception de proteines pour la conception de bibliotheques de proteines a antigenicite modifiee
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
EP1974752B1 (fr) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Cible infracellulaire de protéines thérapeutiques
EP1395293B1 (fr) 2001-05-14 2009-07-22 Gbp Ip, Llc Vecteurs lentiviraux codant des facteurs de coagulation utiles pour la therapie genique
EP1903054A3 (fr) 2001-06-05 2008-07-23 CureVac GmbH Composition pharmaceutique contenant une ARNm stabilisée et optimisée pour la translation dans ses zones codées
WO2003012054A2 (fr) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux
CA2462628C (fr) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Vecteurs lentiviraux a expression reduite
SG10202108118RA (en) 2001-11-13 2021-08-30 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040230380A1 (en) 2002-01-04 2004-11-18 Xencor Novel proteins with altered immunogenicity
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
ATE474460T1 (de) 2002-12-13 2010-08-15 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
AU2004293371A1 (en) 2003-07-03 2005-06-09 Avatar Biotechnologies, Inc. Methods for obtaining molecules with reduced immunogenicity
GB0316089D0 (en) 2003-07-09 2003-08-13 Xo Bioscience Ltd Differentiation method
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
HUE054805T2 (hu) 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
EP3085389A1 (fr) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Procédé d'augmentation de la fonction d'un vecteur aav
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
EP1757703A3 (fr) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Vecteur gammarétroviral auto-inactivant ( SIN)
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
EP1757702A1 (fr) 2005-08-24 2007-02-28 Medizinische Hochschule Hannover Vecteur gammaretroviral auto-inactivant ( SIN)
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
US8603457B2 (en) 2005-12-02 2013-12-10 University Of Rochester Nonsense suppression and genetic codon alteration by targeted modification
US8706219B2 (en) 2005-12-22 2014-04-22 Board Of Regents, The University Of Texas System Method and apparatus for monitoring an organ of a patient
KR100787393B1 (ko) * 2006-03-23 2007-12-21 학교법인 한림대학교 세포 도입성 ｆｋ506 결합 단백질의 융합 단백질
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
US20090181458A1 (en) 2006-12-04 2009-07-16 Thomas David Reed Tubulo-vesicular structure localization signals
WO2008140615A2 (fr) 2006-12-21 2008-11-20 Novozymes, Inc. Séquences stabilisatrices d'arn messager modifié permettant l'expression de gènes dans des cellules bactériennes
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US7588923B2 (en) 2007-03-02 2009-09-15 Richmond Chemical Corporation Method to increase the yield and improve purification of products from transaminase reactions
DK2147104T3 (en) 2007-05-21 2015-12-14 Danisco Us Inc USING A ASPARAGINPROTEASE- (NSP24) SIGNAL SEQUENCE FOR heterologous protein EXPRESSION
CA2691785C (fr) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes d'il-15 et il-15r alpha et leurs utilisations
EP2173872B1 (fr) 2007-06-29 2014-04-02 CellScript, Inc. Adn de copie et arn sens
CA2695433C (fr) 2007-08-03 2025-05-06 Institut Pasteur Vecteurs de transfert de gènes antiviraux et leurs applications médicinales
WO2009045308A2 (fr) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Production améliorée de lymphocytes t cytotoxiques par suppression de foxp3 à médiation assurée par il-21
EP2072618A1 (fr) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Utilisation d'ARN pour la reprogrammation de cellules somatiques
WO2009127230A1 (fr) 2008-04-16 2009-10-22 Curevac Gmbh Arn(m) modifié pour supprimer ou éviter une réponse immunostimulante et composition immunosuppressive
US8357511B2 (en) 2008-08-01 2013-01-22 The Regents Of The University Of Michigan Protein purification tags and uses thereof
WO2010042490A1 (fr) 2008-10-06 2010-04-15 Boston Medical Center Corporation Système de vecteur lentiviral unique pour dérivation de cellules souches pluripotentes induites (ips)
CA2753362C (fr) 2009-02-24 2018-06-19 The Scripps Research Institute Re-ingenierie de structure primaire d'arnm pour une production amelioree de proteines
US20100260739A1 (en) 2009-03-09 2010-10-14 Bioatla, Llc Mirac Proteins
WO2010113037A1 (fr) 2009-04-03 2010-10-07 Centre National De La Recherche Scientifique Vecteurs de transfert de gènes comprenant des isolants génétiques et procédés d'identification d'isolants génétiques
EP2427577A4 (fr) 2009-05-04 2013-10-23 Hutchinson Fred Cancer Res Vecteurs rétroviraux pseudotypés d'enveloppe du virus cocal (vesiculovirus)
WO2010134537A1 (fr) 2009-05-20 2010-11-25 東レ株式会社 Peptides à perméabilité membranaire cellulaire
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
EP2451475A2 (fr) 2009-07-06 2012-05-16 Novartis AG Molécules d'arn autorépliquantes et leurs utilisations
EP3165234B1 (fr) 2009-07-31 2019-04-03 ethris GmbH Arn avec une combinaison de nucléotides non modifiés et modifiés pour l'expression de protéines
EP2475771B1 (fr) 2009-09-10 2019-06-05 Biocon Limited Nouvelles protéines de fusion prolipase-trypsinogène bovin
WO2011034580A2 (fr) 2009-09-18 2011-03-24 University Of Houston Petits modulateurs peptidiques du trafic des canaux potassium
US20130012687A1 (en) 2009-09-21 2013-01-10 The Board Of Trustees Of The Leland Stanford Junior University Inducible self-cleaving protease tag and method of purifying recombinant proteins using the same
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (fr) 2009-10-29 2011-05-19 Trustees Of Dartmouth College Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
US8993741B2 (en) 2009-11-17 2015-03-31 The Trustees Of The University Of Pennsylvania SMNdelta7 degron: novel compositions and methods of use
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
KR101878502B1 (ko) 2009-12-07 2018-07-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제
WO2011109726A2 (fr) 2010-03-05 2011-09-09 Bioatla Llc Anticorps homologues multispécifiques
EP3072961A1 (fr) 2010-04-16 2016-09-28 Children's Medical Center Corporation Expression de polypeptides prolongée à partir d'arn modifiés, synthétiques et leurs utilisations
WO2011140284A2 (fr) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Ligands super agonistes conditionnels des lymphocytes t cytotoxiques (ctl) pour promotion de réponses de ctl spécifiques de tumeurs
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
EP2619229B1 (fr) 2010-09-21 2016-04-06 Altor BioScience Corporation Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation
US9512401B2 (en) 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
DK2643468T3 (en) 2010-11-22 2018-09-24 Amicus Therapeutics Inc Hitherto UNKNOWN SIGNAL SEQUENCES TO IMPROVE EXPRESSION AND SECRETARY OF RECOMBINANT ENZYMES AND OTHER PROTEINS
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012083424A1 (fr) 2010-12-21 2012-06-28 The University Of Western Ontario Nouvelles séquences d'acides aminés de liaison pour immobilisation de ligands
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
EP2708561A4 (fr) 2011-03-15 2014-09-24 Univ Yonsei Iacf Bio-aiguille
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
WO2013051718A1 (fr) 2011-10-07 2013-04-11 国立大学法人三重大学 Récepteur d'antigène chimérique
IN2014CN02906A (fr) * 2011-10-20 2015-07-03 Us Health
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013091661A2 (fr) 2011-12-23 2013-06-27 Aarhus Universitet Etiquette d'affinité protéique résistante à la protéolyse
WO2013096955A1 (fr) 2011-12-23 2013-06-27 Case Western Reserve University Modification de gène ciblée à l'aide d'un virus adéno-associé recombinant hybride
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
HK1207654A1 (en) 2012-04-27 2016-02-05 Bioatla, Llc Modified antibody regions and uses thereof
CN104321425B (zh) 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
KR102023401B1 (ko) 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
WO2013172926A1 (fr) * 2012-05-14 2013-11-21 Yale University Biomarqueurs immunes et analyses pour prévoir la réponse clinique à une immunothéraphie contre le cancer
EP4279579A3 (fr) 2012-06-28 2024-02-21 University Of Central Florida Research Foundation Incorporated Procédés et compositions pour des cellules tueuses naturelles
RU2015103816A (ru) 2012-07-09 2016-08-27 Ф.Хоффманн-Ля Рош Аг ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
GB201212902D0 (en) 2012-07-20 2012-09-05 Univ Singapore Combinatoric encoding methods for microarrays
WO2014046481A1 (fr) 2012-09-19 2014-03-27 주식회사 카엘젬백스 Peptide de pénétration cellulaire, conjugué le comprenant, et composition comprenant le conjugué
WO2014053879A1 (fr) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Peptides pénétrant dans les cellules pour l'administration intracellulaire de molécules
WO2014053880A1 (fr) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Peptides pénétrant dans les cellules pour l'administration intracellulaire de molécules
RU2015113348A (ru) 2012-10-08 2016-11-27 Ф. Хоффманн-Ля Рош Аг Проникающие в клетки пептиды, связывающие интерферон-регулирующий фактор 5
WO2014066527A2 (fr) 2012-10-24 2014-05-01 Admune Therapeutics Llc Formes d'il-15r alpha, cellules exprimant des formes d'il-15r alpha, et utilisations thérapeutiques d'il-15r alpha et de complexes il-15/il-15r alpha
US9444624B2 (en) 2012-11-02 2016-09-13 Facebook, Inc. Providing user authentication
EP2928909B1 (fr) 2012-12-07 2018-08-01 The Queen's University Of Belfast Peptide amphipathique
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014121005A1 (fr) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lignées cellulaires d'encapsidation de vecteurs rétroviraux et procédés de purification et de production de particules rétrovirales
SI3300745T1 (sl) * 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
WO2014152932A1 (fr) * 2013-03-14 2014-09-25 Board Of Regents, The University Of Texas System Miarn pour le traitement du cancer et pour l'utilisation avec des immunothérapies adoptives
EP3974520A1 (fr) * 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
AU2014314149B2 (en) * 2013-08-28 2019-12-19 Pci Biotech As Compound and method for vaccination and immunisation
WO2015039100A1 (fr) 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Enrichissement de cd137 pour la sélection de lymphocytes d'infiltration tumorale efficaces
CN105829349B (zh) * 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
HUE045872T2 (hu) 2014-05-21 2020-01-28 Entrada Therapeutics Inc Sejteket penetráló peptidek és ezek elõállítására és alkalmazására szolgáló eljárások
US10300118B2 (en) 2014-05-29 2019-05-28 Procell Therepautics Inc. Cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof
US20160060313A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Angiogenic Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Angiogenic Compositions Comprising the Same
EP3189152A4 (fr) 2014-09-03 2018-04-04 BioAtla LLC Découverte et production de protéines biologiques conditionnellement actives dans les mêmes cellules hôtes eucaryotes de production
WO2016061368A1 (fr) 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions et méthodes pour le traitement de tumeurs malignes b-lymphoïdes
EP3245288A1 (fr) * 2015-01-12 2017-11-22 Pieris Pharmaceuticals GmbH Lymphocyte t produits par génie génétique et leurs utilisations
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016134284A1 (fr) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Récepteurs antigéniques chimériques et leurs utilisations
EP3280795B1 (fr) 2015-04-07 2021-03-24 Novartis AG Combinaison de traitement à l'aide du récepteur antigénique chimérique et de derivés de l'amino pyrimidine
AU2016245347B2 (en) 2015-04-10 2021-01-28 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016210350A1 (fr) 2015-06-25 2016-12-29 Amyris, Inc. Dégrons dépendant du maltose, promoteurs sensibles au maltose, constructions de stabilisation, et leur utilisation dans la production de composés non cataboliques
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
WO2017015427A1 (fr) 2015-07-21 2017-01-26 Novartis Ag Méthodes pour améliorer l'efficacité et l'expansion de cellules immunitaires
US10562952B2 (en) 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
WO2017175072A1 (fr) 2016-04-08 2017-10-12 Feldan Bio Inc. Disruption génique basée sur une navette peptidique
EP3443001B1 (fr) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Systèmes de biocircuits régulés
CN110214150A (zh) * 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules
WO2018231759A1 (fr) * 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Compositions de pde5 et méthodes d'immunothérapie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE JUILLERAT ET AL: "Design of chimeric antigen receptors with integrated controllable transient functions", SCIENTIFIC REPORTS, vol. 6, 11 January 2016 (2016-01-11), pages 18950, XP055271820, DOI: 10.1038/srep18950 *
MARI IWAMOTO ET AL: "A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System", CHEMISTRY & BIOLOGY, vol. 17, no. 9, 1 September 2010 (2010-09-01), GB, pages 981 - 988, XP055552908, ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2010.07.009 *
See also references of WO2018161017A1 *

Also Published As

Publication number Publication date
JP7341900B2 (ja) 2023-09-11
CA3055202A1 (fr) 2018-09-07
EP3589646A1 (fr) 2020-01-08
AU2018227583A1 (en) 2019-10-17
KR102746901B1 (ko) 2024-12-26
JP2025185029A (ja) 2025-12-18
CN110831961A (zh) 2020-02-21
AU2023214349B2 (en) 2026-01-29
SG10202001869VA (en) 2020-04-29
KR20200010181A (ko) 2020-01-30
SG11201907922PA (en) 2019-09-27
JP2023164900A (ja) 2023-11-14
JP2020511529A (ja) 2020-04-16
AU2018227583B2 (en) 2023-06-01
AU2023214349A1 (en) 2023-08-31
CN110831961B (zh) 2024-01-02
WO2018161017A1 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EP3735685A4 (fr) Panneau d'affichage
EP3445407A4 (fr) Compositions et méthodes d'immunothérapie cellulaire
MA46643A (fr) Méthodes et compositions pour le mappage d'arn
EP3750149C0 (fr) Panneau d'affichage
EP3607587A4 (fr) Panneau d'affichage
MA44725A (fr) Formulations d'un inhibiteur de lsd1
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3446194A4 (fr) Raccourcis d'application pour carplay
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
EP3656821A4 (fr) Composition d'asphalte
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
EP3798719A4 (fr) Panneau d'affichage
CA185201S (fr) Boucle d'oreilles
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
MA49006A (fr) Inhibiteurs d'ip6k
EP3752194A4 (fr) Compositions et méthodes d'immunothérapie anti-tumorale
EP3426349A4 (fr) Procédés et compositions pour inhiber l'expression de pmp22
EP4058062A4 (fr) Compositions et méthodes pour l'immunothérapie
EP3820980A4 (fr) Compositions d'esterquats
EP3478315A4 (fr) Méthodes et compositions d'inhibition du récepteur immunitaire inhibiteur
EP3746058A4 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRISKIN, MICHAEL JOSEPH

Inventor name: OLS, MICHELLE LYNN

Inventor name: DOLINSKI, BRIAN

Inventor name: SUN, DEXUE

Inventor name: EZELL, TUCKER

Inventor name: LI, DAN JUN

Inventor name: KOSMIDER, NICOLE

Inventor name: BALAKRISHNAN, VIJAYA

Inventor name: SURI, VIPIN

Inventor name: HELLER, SCOTT FRANCIS

Inventor name: KULKARNI, ABHISHEK

Inventor name: ELPEK, KUTLU GOKSU

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20191001

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014505000

Ipc: C12N0009060000

A4 Supplementary search report drawn up and despatched

Effective date: 20201218

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/55 20060101ALI20201214BHEP

Ipc: C07K 14/705 20060101ALI20201214BHEP

Ipc: C07K 16/30 20060101ALI20201214BHEP

Ipc: A61K 31/505 20060101ALI20201214BHEP

Ipc: C12N 9/64 20060101ALI20201214BHEP

Ipc: A61K 35/00 20060101ALI20201214BHEP

Ipc: A61K 31/519 20060101ALI20201214BHEP

Ipc: C12N 9/02 20060101ALI20201214BHEP

Ipc: C07K 14/54 20060101ALI20201214BHEP

Ipc: A61P 37/02 20060101ALI20201214BHEP

Ipc: A61K 38/00 20060101ALI20201214BHEP

Ipc: C07K 14/725 20060101ALI20201214BHEP

Ipc: C12N 15/62 20060101ALI20201214BHEP

Ipc: A61P 35/00 20060101ALI20201214BHEP

Ipc: A61K 39/00 20060101ALI20201214BHEP

Ipc: C07K 16/28 20060101ALI20201214BHEP

Ipc: A61K 39/39 20060101ALI20201214BHEP

Ipc: A61K 35/14 20150101ALI20201214BHEP

Ipc: C12N 9/06 20060101AFI20201214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241202